Funda Meric-Bernstam, MDEnriched profile
Department Chair, Investigational Cancer Therapeutics; Medical Director, Khalifa Institute for Personalized Cancer Therapy; Nellie B. Connally Chair in Breast Cancer; Professor, Breast Surgical Oncology · The University of Texas MD Anderson Cancer Center
Overview
Updated 14 Jul 2026
Funda Meric-Bernstam, M.D., is Department Chair, Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, Houston, TX. The public record shows 2,643 publications with 108,262 citations (h-index 148), centered on Cancer Genomics and Diagnostics, HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 20 companies, 10 NIH-funded awards (2001–2026).
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Cancer Genomics and Diagnostics
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 20 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 105 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 698.
Clinical & industrytrials, payments and federal funding
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- PRE-I-SPY Phase I/Ib Oncology Platform Program
Sponsor: QuantumLeap Healthcare Collaborative
InvestigatorPhase 1RecruitingNCT05868226 - Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Sponsor: AstraZeneca
InvestigatorPhase 1/PHASE2RecruitingNCT05797168 - Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
Sponsor: National Cancer Institute (NCI)
InvestigatorPhase 2Active, not recruitingNCT03872427
Industry payments
Updated 14 Jul 2026
20 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim International GmbHProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20253 payments
- Daiichi Sankyo Inc.Program year20254 payments
NIH funding
Updated 14 Jul 2026
10 NIH research awards on record, funded 2001–2026 per NIH RePORTER. The latest:
- Texas EXperimental Cancer Therapeutics Network - TEX CTN
University of Tx Md Anderson Can Ctr
FY2026$1,519,430UM1CA186688 - Discovery of the next-generation RET-targeted drugs based on nicotinamide scaffold
University of Oklahoma Hlth Sciences Ctr
FY2026$579,728R01CA273168 - A phase II multi-center trial evaluating dual targeting of the PI3K/AKT and NOS pathways for treating metaplastic breast cancer (MpBC)
Methodist Hospital Research Institute
FY2026$367,053U01CA268813
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03KRAS <sup>G12C</sup> Inhibition with Sotorasib in Advanced Solid Tumors1,694 citations2020
- 04PD-L1 Expression in Triple-Negative Breast Cancer1,407 citations2014
- 05
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership rolesjournal and society appointments
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
- Department Chair
Investigational Cancer Therapeutics (Phase I Program)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mdanderson.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →meetings.asco.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
Secondary affiliationsappointments beyond the home institution
- Regular Member
Professor (Cancer Biology and Therapeutics and Pharmacology Program), UTHealth Houston Graduate School of Biomedical Sciences
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →gsbs.uth.edu ↗ - Member
Clinical Advisory Board, Sutro Biopharma, Inc.
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sutrobio.com ↗
Media & interviewspress, podcasts and appearances
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →urotoday.com ↗
- Video interview
"Trastuzumab Deruxtecan Safety in HER2-Expressing Solid Tumors" -- Oncology Data Advisor, 2023 ASCO Annual Meeting
2023provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncdata.com ↗ - Video
"Funda Meric-Bernstam, MD on HER2-Expressing Solid Tumors: Efficacy and Safety of Trastuzumab Deruxtecan" -- ASCO Post, 2023 ASCO Annual Meeting
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- Doximity
doximity.com/pub/funda-meric-bernstam-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Funda-Meric-Bernstam
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/christopherrflowersmd_congratulations-to-dr-funda-meric-bernstam-activity-7161254840520638467-rs4L
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/khandan-keyomarsi-05a4a01_funda-meric-bernstam-md-elected-to-national-activity-7254615632178995201-av_s
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/posts/mdandersoncancercenter_dr-funda-meric-bernstam-explains-how-clinical-activity-6791358350312439808-EZF7
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
- 5,579
- publications
- 233
- h-index
- 24
- trials
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
- 1,905
- publications
- 187
- h-index
- 1
- trial
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
- 1,745
- publications
- 154
- h-index
- 22
- trials
Ignacio Wistuba, MD
The University of Texas MD Anderson Cancer Center
- 2,842
- publications
- 156
- h-index
- 6
- NIH grants